Mediwound Ltd. (MDWD)

Trade MDWD now with
9/16/2020 7:43:55 AM MediWound Announces FDA Acceptance Of BLA For NexoBrid For Severe Thermal Burns In Adults
9/16/2020 7:39:53 AM MediWound Says FDA Accepted For Review Its Recently Submitted BLA For NexoBrid
6/30/2020 7:13:17 AM MediWound Submits BLA To FDA Seeking Approval Of NexoBrid For Thermal Burns
3/30/2020 7:40:48 AM MediWound Temporarily Suspend Patient Enrollment In EscharEx Phase 2 Study
3/3/2020 6:09:25 AM BARDA Expands Awarded Contract With MediWound
1/2/2020 7:35:45 AM MediWound Inks Deal Granting Balance Medical Exclusive Rights To Market NexoBrid In Australia, New Zealand And Singapore
12/3/2019 8:41:44 AM MediWound Initiates U.S. Phase 2 Adaptive Design Study Of EscharEx For Treatment Of Venous Leg Ulcers
10/2/2019 7:36:47 AM Vericel And MediWound Begin U.S. NexoBrid Expanded Access Treatment Protocol
1/22/2019 6:32:41 AM MediWound Announces Positive Top-Line Results From Pivotal Phase 3 Study (DETECT) In NexoBrid
11/13/2018 7:25:14 AM MediWound Q3 Net Loss $2.9 Mln Or $0.11/Shr Vs Net Loss $11.0 Mln Or $0.49/Shr Last Year
9/5/2018 7:03:01 AM MediWound Receives Marketing Authorization From Russia's Ministry Of Health
8/7/2018 7:19:58 AM MediWound Q2 Net Loss $4.2 Mln Or $0.15 Per Share
6/19/2018 7:06:12 AM MediWound Expands NexoBrid Phase 3 Children Innovation Debridement Study To The U.S.
6/11/2018 7:04:09 AM MediWound Completes Enrollment In NexoBrid U.S. Phase 3 DETECT Study
5/29/2018 8:06:28 AM MediWound: FDA Clears Development Pathway For NexoBrid® For Sulfur Mustard Injuries
5/10/2018 7:11:49 AM MediWound Q1 Net Loss Flat At $4.6 Mln